NCT06098209View on ClinicalTrials.gov

Dexmedetomidine and Propofol in Mechanically Ventilated Patients by Using Salivary Alpha-amylase as a Stress Marker

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 24, 2023

Primary Completion Date

April 11, 2024

Study Completion Date

April 11, 2024

Conditions
DexmedetomidinePropofolMechanical VentilationSalivary Alpha AmylaseStress
Interventions
DRUG

Dexmedetomidine

Patient will receive dexmedetomidine 0.2-1.4 μg/kg/h.

DRUG

Propofol

Patient will receive propofol 0.3-4 mg/kg/h.

Trial Locations (1)

31527

Tanta University, Tanta

All Listed Sponsors
lead

Tanta University

OTHER

NCT06098209 - Dexmedetomidine and Propofol in Mechanically Ventilated Patients by Using Salivary Alpha-amylase as a Stress Marker | Biotech Hunter | Biotech Hunter